An official website of the United States government
Study of XB010 in Subjects With Solid Tumors
Trial Status: active
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and
preliminary antitumor activity of XB010 as a single agent and in combination with
pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom
alternative therapies do not exist or available therapies are intolerable or no longer
effective.
Inclusion Criteria
- Age 18 years or older on the day of consent.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
- Adequate organ and marrow function.
- Cytologically or histologically and radiologically confirmed solid tumor that is
inoperable, locally advanced, metastatic, or recurrent.
- The Cohort Expansion stage will enroll subjects with multiple tumor types
(non-small cell lung cancer, hormone-receptor-positive breast cancer, head and
neck cancer, esophageal squamous cell, triple-negative breast cancer).
- Capable of understanding and complying with the protocol requirements and must have
signed the informed consent document.
Additional locations may be listed on ClinicalTrials.gov for NCT06545331.
Locations matching your search criteria
United States
California
Duarte
City of Hope Comprehensive Cancer Center
Status: Active
Name Not Available
Georgia
Atlanta
Emory University Hospital/Winship Cancer Institute
Status: Approved
Name Not Available
Missouri
Saint Louis
Siteman Cancer Center at Washington University
Status: Active
Name Not Available
Oklahoma
Oklahoma City
University of Oklahoma Health Sciences Center
Status: Active
Name Not Available
Texas
Houston
M D Anderson Cancer Center
Status: Active
Name Not Available
This study consists of Dose-Escalation and Cohort-Expansion Stages. The Dose-Escalation
Stage is designed to determine the maximum tolerated dose (MTD) and/or recommended
dosage(s) for expansion (RDE[s]) of XB010 as a single agent, and to evaluate XB010
monotherapy RDE(s) in combination with pembrolizumab. The Cohort-Expansion Stage is
designed to explore the clinical activity and further characterize the safety and
tolerability of XB010 as monotherapy in multiple tumor-specific cohorts.
